Diagnosis and management of Influenza

PAYAM TABARSI

NRITLD

SBMU

- Influenza is an acute viral respiratory infection that causes significant morbidity and mortality worldwide.
- Three types of influenza cause disease in humans. Influenza A is the type most responsible for causing pandemics because of its high susceptibility to antigenic variation. I
- influenza is highly contagious, and the hallmark of infection is abrupt onset of fever, cough, chills or sweats, myalgias, and malaise

- Atypical gastrointestinal symptoms such as vomiting and diarrhea can occur in children.
- A minority of patients, especially older adults, young children, and those

with medical comorbidities, will experience severe disease due to viral or

secondary bacterial pneumonia with respiratory and multiorgan failure

People at Increased Risk of Complications from Influenza

People with coexisting medical conditions

Any condition that may compromise the handling of respiratory secretions (e.g., neuromuscular diseases, cerebral palsy, stroke, seizure disorder, dementia)

Asthma or other chronic pulmonary disease

Chronic kidney disease

Chronic liver disease

Heart disease (acquired or congenital)

Immunosuppression (e.g., HIV infection, cancer, transplant recipients, use of immunosuppressive medications)

Long-term aspirin therapy in patients younger than 19 years

Metabolic disorders (acquired [e.g., diabetes mellitus] or inherited [e.g., mitochondrial disorders])

Morbid obesity

Sickle cell anemia and other hemoglobinopathies

Special groups

Adults 65 years and older

American Indians and Alaska Natives

Children younger than 5 years (particularly those younger than 2 years)

Institutionalized adults (e.g., residents of nursing homes or chronic care facilities)

Pregnant and postpartum women (up to 2 weeks postpartum, including pregnancy loss)

Complications of Influenza

Cardiovascular²⁶

Cerebrovascular accidents Ischemic heart disease Myocarditis

Hematologic²⁶

Hemolytic uremic syndrome Hemophagocytic syndrome Thrombotic thrombocytopenic purpura

Musculoskeletal^{19,26}

Myositis

Rhabdomyolysis

Neurologic²⁶

Acute disseminated encephalomyelitis

Encephalitis

Guillain-Barré syndrome

Postinfluenza encephalopathy (neurologic symptoms occurring after resolution but within 3 weeks of primary infection) Reye syndrome

Ocular²⁶

Conjunctivitis (most common) **Optic neuritis** Retinopathy Uveal effusion syndrome Pulmonary^{8,25,27} Acute respiratory distress syndrome Diffuse alveolar hemorrhage Hypoxic respiratory failure Primary viral pneumonia Secondary bacterial pneumonia Renal²⁶ Acute kidney injury (e.g., acute tubulointerstitial nephritis,

glomerulonephritis, minimal change disease) Multiorgan failure

- In outpatient and emergency department settings, testing for influenza virus is not necessary to start antiviral treatment in a patient with suspected influenza infection, especially during seasons when influenza A and B viruses are circulating in the local community.
- The diagnosis is made clinically based on presenting signs and symptoms, or if the patient has a suspected influenza-associated complication, such as exacerbation of a chronic disease, concomitant pneumonia, or rhabdomyolysis

- A symptom-only clinical prediction rule may aid clinicians in diagnosing influenza.
- It assigns 2 points for fever and cough, 2 points for myalgias, 1 point for chills or sweats, and 1 point for symptom onset within the past 48 hours.
- Patients with 2 or fewer points are at low risk of influenza, whereas those with 4 or more points are at high risk and may be considered for empiric treatment.

• According to the CDC, influenza testing can be considered when the

results will modify management or when a patient with signs or

symptoms of influenza is hospitalized.

- The Infectious Diseases Society of America (IDSA) suggests testing if the results will curtail the use of unnecessary antibiotics or laboratory testing, or result in prophylactic treatment of high-risk household contacts.
- A prospective study performed at a university health clinic found that rapid polymerase chain reaction testing decreased antibiotic prescriptions as well as the likelihood of the patient returning for a second visit within two weeks

Accuracy of Point-of-Care Tests for Influenza						
			Low prevalence (5%)		High prevalence (33%)	
Test	Positive likelihood ratio	Negative likelihood ratio	Positive predictive value (%)	Negative predictive value (%)	Positive predictive value (%)	Negative predictive value (%)
Influenza A						
Adults						
Commercially available rapid influenza tests	85	0.58	82	3	98	22
Digital immunoassays	23	0.25	55	1	92	11
Rapid nucleic acid amplification tests	44	0.13	70	1	96	6
Children						
Commercially available rapid influenza tests	76	0.39	80	2	97	16
Digital immunoassays	46	0.13	71	1	96	6
Rapid nucleic acid amplification tests	90	0.10	83	0	98	5
Influenza B						
Adults						
Commercially available rapid influenza tests	332	0.67	95	3	99	25
Digital immunoassays	47	0.44	71	2	96	18
Rapid nucleic acid amplification tests	108	0.24	85	1	98	11
Children						
Commercially available rapid influenza tests	164	0.34	90	2	99	15
Digital immunoassays	69	0.18	78	1	97	8
Rapid nucleic acid amplification tests	192	0.04	91	0	99	2

• Treatment with an anti-influenza drug is an option, with the decision

to prescribe based on balancing potential benefits, harms, cost, and

patient preferences

• In otherwise healthy adults and children, the clinical benefit is greatest

when treatment is initiated within 24 hours of symptom onset.

• The primary benefit of treatment is a decrease in symptom duration by

approximately 24 hours when treatment is initiated within 36 hours, and a

reduction in disease severity

• Among adults and children with influenza in the outpatient setting


who are treated with an NA inhibitor, systematic reviews of published


and unpublished randomized trials found no decrease in

hospitalizations or death

• However, in hospitalized adults and children, three observational

studies found an association between the use of NA inhibitors and mortality benefit





antiviral treatment for hospitalized

Test for influenza; start empiric antiviral treatment for hospitalized patients as soon as possible while results are pending.^{4,5,6,7,8} Proper interpretation of testing results is important.⁴

if worsening.

- Antiviral treatment is recommended as early as possible for any patient with confirmed or suspected influenza who :
- is hospitalized
- has severe, complicated, or progressive illness
- is at higher risk for influenza complications

- When indicated, antiviral treatment should be started as soon as possible after illness onset, ideally within 48 hours of symptom onset for the greatest clinical benefit
- Observational studies have reported that antiviral treatment of influenza can have clinical benefit in patients with severe, complicated or progressive illness, and in hospitalized patients when started after 48 hours of illness onset.

- Decisions about starting antiviral treatment should not wait for laboratory confirmation of influenza
- Clinical benefit is greatest when antiviral treatment is started as close to illness onset as possible.

• Antiviral treatment with oral oseltamivir, inhaled zanamivir, intravenous peramivir, or oral baloxavir also can be considered for any previously healthy, symptomatic outpatient not at higher risk for influenza complications, who is diagnosed with confirmed or suspected influenza, on the basis of clinical judgment, if treatment can be initiated within 48 hours of illness onset.

- The optimal duration and dosing of antiviral treatment are uncertain for severe or complicated influenza. Treatment regimens might need to be altered to fit the clinical circumstances.
- Decisions about extended (longer) duration of treatment should be guided by clinical judgment in patients whose illness is prolonged.

- Critically ill patients with respiratory failure can have prolonged influenza viral replication in the lower respiratory tract and might benefit from longer duration of treatment.
- Longer treatment regimens might be necessary in immunocompromised patients who may have prolonged influenza viral replication.
- Such patients are at risk of emergence of influenza viruses with reduced susceptibility or antiviral resistance during or after antiviral

traatmant

 A higher dose of oral or enterically administered oseltamivir has been recommended by some experts (e.g., 150 mg twice daily in adults with normal renal function) for treatment of influenza in immunocompromised patients and in severely ill hospitalized patients.

Drug/formulation	Cost*	Dosages	FDA-approved indications	Contraindications and precautions	
Oseltamivir (Tami- flu), available as oral capsules or	\$50 to \$100 (\$160 to \$310) depending on	Adults and children 13 years and older: 75 mg 2 times per day for 5 days	Prevention of influenza A and B in patients 12 months and older	Contraindicated in people with serious hypersensitivity to osel- tamivir or any component of the product Potential adverse effects include nausea, vomiting, and allergic reactions (e.g., rash, facial swelling) May use during pregnancy; pre- ferred drug for influenza treatment; consider increased dose in preg- nant women who are hospitalized with influenza complications; risk of embryo-fetal toxicity not expected based on human data	
suspension	dosage	Children: 2 weeks to < 12 months of age (any weight): 3 mg per kg 2 times per day for 5 days < 33 lb (15 kg): 30 mg 2 times per day for 5 days 33 to 50 lb (15 to 23 kg): 45 mg 2 times per day for 5 days > 50 to 88 lb (23 to 40 kg): 60 mg orally 2 times per day for 5 days > 88 lb (40 kg): adult dosage	Treatment of uncom- plicated acute influenza A and B in patients 2 weeks and older who have been symptomatic for no more than 48 hours		
Zanamivir (Relenza), available as powder for inhalation Intravenous formu- lation available only as an emergency investigative new drug	NA (\$65)	Adults and children 7 years and older: 10 mg 2 times per day for 5 days (2 doses should be taken on the first day of treatment, provided there is at least 2 hours between doses; on subsequent days, doses should be about 12 hours apart at approximately the same time each day)	Prevention of influenza A and B in patients 5 years and older Treatment of uncom- plicated acute influenza A and B in patients 7 years and older who have been symptomatic for no more than 48 hours	Contraindicated in people with milk allergy, underlying reactive airway disease (e.g., asthma, chronic obstructive pulmonary disease), or history of allergic reaction to zanamivir or any com- ponent of the product Potential adverse effects include headaches, diarrhea, nausea, vom- iting, allergic reaction, nasal symp- toms, bronchitis, cough, sinusitis,	

May use during pregnancy; risk of embryo-fetal toxicity not expected based on human data

dizziness, fever, chills, arthralgia, and articular rheumatism; serious and sometimes fatal cases of bron-

chospasm have occurred

Drug/formulation	Cost*	Dosages	FDA-approved indications	Contraindications and precautions
Peramivir (Rapivab), \$1,0 available as solu- tion for injection	\$1,000	Adults and children 13 years and older: single dose of 600 mg	Treatment of uncom- plicated acute influenza A and B in patients 2 years and	Contraindicated in people with serious hypersensitivity or anaphylaxis to peramivir or any component of the product
		Children 2 to 12 years of age: single dose of 12 mg per kg (up to 600 mg)	older who have been symptomatic for no more than 48 hours	Potential adverse effects include diarrhea, nausea, vomiting, and neutropenia
				Weigh risks and benefits during pregnancy; no human data available; no known risk of embryo-fetal toxicity based on animal data at 8 times the recom- mended human dose; possible risk of embryo-fetal toxicity with continuous intravenous infusion based on limited animal data
Baloxavir (Xofluza), N available as oral tablets	NA (\$160)	Adults and children 12 years and older: 88 to 174 lb (40 to 79 kg): single dose of 40 mg ≥ 175 lb (80 kg): single dose of 80 mg	Treatment of uncom- plicated acute influenza in patients 12 years and older who	Contraindicated in people with a history of hypersensitivity to baloxavir or any component of the product
			have been symptom- atic for no more than 48 hours	Potential adverse effects include diarrhea, bronchitis, nasopharyngi- tis, headache, and nausea
				Avoid use during pregnancy; no human data available; no known risk of fetal harm based on animal data at 5 and 7 times the maximum recommended human dose

Antiviral Agent	Activity Against	Use	Recommended For	Not Recommended for Use in	Adverse Events
Oral Influenza Oseltamivir A and B	Treatment	Any age ¹	N/A	Adverse events: nausea, vomiting, headache. Post marketing	
		Chemo- prophylaxis	3 months and older ¹	N/A	reports of serious skin reactions and sporadic, transient neuropsychiatric events ²

• The CDC and the IDSA recommend antiviral therapy for patients with

severe or progressive illness, who are at high risk of influenza-

associated complications, or who are hospitalized.

• Although early treatment is most beneficial, treatment should be

initiated in these patients regardless of symptom duration

• The IDSA also recommends that treatment be considered for

household contacts of people at high risk of influenza-associated complication

- Oseltamivir is the preferred treatment for patients with severe influenza.
- Intravenous peramivir is an option for these patients if there are contraindications to or concerns about reduced bioavailability of oral oseltamivir.
- Inhaled zanamivir is not recommended for patients with severe disease because it has not been well studied.
- It is contraindicated in patients requiring mechanical ventilation and in those with underlying lung disease because of the risk of bronchospasm

• Adamantanes (amantadine and rimantadine [Flumadine]) are approved for

influenza treatment but are not currently recommended.

• These medications are not active against influenza B, and most influenza A

strains have shown adamantane resistance for the past 10 years

• There is no demonstrated benefit to treating patients with more than one antiviral agent or using higher than recommended dosages

- However, extended treatment courses may be indicated in critically ill patients.
- Supportive treatment and management of complications, including potential


secondary bacterial pneumonia, are paramount

- Corticosteroids are not recommended unless the patient has another approved indication for their use.
- Treatment resistance should be considered in patients who take antivirals and

develop lower respiratory tract disease, although this is less likely than natural


disease progression and more common in immunosuppressed patients


- Pregnancy is an independent risk factor for complicated influenza. The risk of maternal death increases with each trimester and continues for four weeks postpartum.
- Oseltamivir has good safety data in pregnancy, and the CDC recommends it as first-line treatment for pregnant women. No change in dosing is necessary.





Pathogen Group	Pathogen
Common or core	
Gram-positive bacteria	Streptococcus pneumoniae, methicillin-susceptible Staphylococcus aureus, Strep. pyogenes, other streptococci
Gram-negative bacteria	Hemophilus influenzae, Moraxella catarrhalis, Enterobacteriaceae (e.g., Klebsiella pneu- moniae)
Atypical bacteria	Legionella pneumophila, Mycoplasma pneumoniae, Chlamydophila pneumoniae
Respiratory viruses	Influenza virus, SARS-CoV-2, respiratory syncytial virus, parainfluenza virus, human meta- pneumovirus, rhinoviruses, common human coronaviruses


Uncommon or infrequent		
Gram-positive bacteria	Methicillin-resistant <i>Staph. aureus</i> , nocardia spe- cies, <i>Rhodococcus equi</i>	
Gram-negative bacteria	Enterobacteriaceae, including extended-spectrum beta-lactamases or carbapenem-resistant enterobacteriaceae; nonfermenting ba- cilli (e.g., pseudomonas or acinetobacter); <i>Francisella tularensis</i>	
Atypical bacteria	Chlamydia psittaci, Coxiella burnetii	
Mycobacteria	<i>Mycobacterium tuberculosis</i> , nontuberculous mycobacteria	
Viruses	Cytomegalovirus, herpes simplex, varicella zoster, MERS-CoV	
Fungi	Pneumocystis jirovecii, aspergillus species, muco- rales species, histoplasma species, cryptococ- cus species, blastomyces species, coccidioi- des species	
Parasites	Strongyloides stercoralis, Toxoplasma gondii	



















P. Koehler et al. / Clinical Microbiology and Infection 25 (2019) 1501–1509





SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Annual influenza vaccination is recommended for all people 6 months and older. ^{15,16}	Α	Reports of expert committees
The decision to begin antiviral treatment should be based on the clinical diagnosis of influenza, not on test results. Laboratory diagnosis should be obtained when results will change clinical management and for patients with severe illness. ^{19,28}		Reports of expert committees
Patients with severe illness or who are at high risk of complications from influenza should receive antiviral treatment regardless of symptom duration, although early treatment is most beneficial. ^{18,28}		Observational studies and a meta-analysis of observational studies
Oseltamivir (Tamiflu), peramivir (Rapivab), baloxavir (Xofluza), or zanamivir (Relenza) may be considered to reduce symptom duration in patients with influ- enza or influenza-like illness, but only if administered within 48 hours—and ideally 24 hours—of symptom onset. ^{18,28}		Systematic review of random- ized trials
Oral oseltamivir is the preferred treatment for influenza during pregnancy. ^{18,28}	В	Pharmacokinetic studies and cohort studies